KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

Veronique Dieras, Giuseppe Curigliano, Miguel Martin, Florence Lerebours, Junji Tsurutani, Marie-France Savard, Katarzyna J Jerzak, Xichun Hu, Luciana Carla Martins de Aquino Pimentel, Ciara C O'Sullivan, Eriko Tokunaga, Alicia Okines, Chiun-Sheng Huang, William Jacot, Joohyuk Sohn, Eduardo Cronemberger Silva, Volkmar Mueller, Shan Yang, Giovanna Granata, Qi Shen, Libero Santarpia, Erika Hamilton, HER2CLIMB-05 Investigators

J Clin Oncol 44(17) 1597-1607

PMID41369677
PMCIDPMC13258094
DOI10.1200/JCO-25-02600
发表日期2025-12-10
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: The HER2CLIMB-05 study (ClinicalTrials.gov identifier: NCT05132582) is investigating the efficacy and safety of adding tucatinib to trastuzumab and pertuzumab as first-line (1L) maintenance therapy in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). METHODS: Patients with centrally confirmed HER2+ MBC without evidence of progression post induction therapy and no or asymptomatic brain metastases (BM) were enrolled. Patients were randomly assigned 1:1 to tucatinib (300 mg) or placebo twice a day combined with trastuzumab/pertuzumab. The primary end point is investigator-assessed progression-free survival (PFS); secondary end points include overall survival (OS), PFS per blinded independent central review, CNS-PFS, and safety. RESULTS: Between March 2022 and July 2024, 654 patients were randomly assigned to tucatinib (n = 326) and placebo (n = 328) arms. All patients were female (median age, 54 years), 69.3% had de novo MBC, 52.6% were hormone receptor-positive, and 12.4% had presence/history of baseline BM. In this primary analysis, PFS was statistically significantly improved with addition of tucatinib versus placebo (hazard ratio, 0.641 [95% CI, 0.514 to 0.799]; P < .0001; median PFS: 24.9 v 16.3 months); a PFS benefit was seen regardless of the presence/absence of BM or hormone receptor status. OS data remain immature. The most common treatment-emergent adverse events (TEAEs) in the tucatinib arm were diarrhea (72.7%), nausea (33.1%), and elevated liver enzymes (ALT: 28.2%; AST: 25.8%), of which 6.1%, 0.9%, 13.5%, and 7.1%, respectively, were grade ≥3. In the tucatinib arm, 13.5% discontinued tucatinib because of TEAEs. CONCLUSION: Tucatinib addition to trastuzumab and pertuzumab demonstrated improvement in PFS with no new safety signals identified and may be an option for 1L maintenance therapy in patients with HER2+ MBC.

KM 提取结果

5 个 Figure · 7 个 KM 面板

进入结果中心
KM Figure1 个面板

FIG 2.

FIG 2. Kaplan–Meier estimate of (A) investigator-assessed PFS in the ITT analysis population and (B) forest plot of subgroup analyses. The random assignment stratification factors used in the Cox proportional-hazards model for computing HRs are diagnosis (de novo or recurrent), hormone receptor status (positive or negative), and presence or history of brain metastases (yes or no). If the subgroup is defined by a random assignment stratification factor, the Cox model is stratified for the random assignment stratification factors other than the one that defines the subgroup. Two-sided P value based on the stratified log-rank test. CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; HER2, human epidermal growth factor receptor; HR, hazard ratio; ITT, intention-to-treat; PBO, placebo; PD, progressive disease; PERT, pertuzumab; PFS, progression-free survival; PR, partial response; SD, stable disease; TRAS, trastuzumab; TUC, tucatinib.

A

PFS

FIG 2. · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure1 个面板

FIG 3.

FIG 3. Kaplan–Meier estimate of OS in the ITT analysis population. HR, hazard ratio; ITT, intention-to-treat; OS, overall survival; PBO, placebo; PERT, pertuzumab; TRAS, trastuzumab; TUC, tucatinib.

OS_Probability

overall survival

FIG 3. · Panel OS_Probability

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel OS_Probability 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
KM Figure1 个面板

FIG A1.

FIG A1. Kaplan-Meier estimate of PFS in the ITT analysis population assessed by blinded independent central review. HR, hazard ratio; ITT, intention-to-treat; PBO, placebo; PERT, pertuzumab; PFS, progression-free survival; TRAS, trastuzumab; TUC, tucatinib.

Kaplan-Meier_estimate_of_PFS_in_the_ITT_analysis_population

PFS

FIG A1. · Panel Kaplan-Meier_estimate_of_PFS_in_the_ITT_analysis_population

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Kaplan-Meier_estimate_of_PFS_in_the_ITT_analysis_population 是同一 FIG A1. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure2 个面板

FIG A2.

FIG A2. Kaplan-Meier estimates of investigator-assessed PFS in patients with (A) hormone receptor–negative and (B) hormone receptor–positive HER2+ MBC. HER2+, human epidermal growth factor receptor 2–positive; HR, hazard ratio; MBC, metastatic breast cancer; PBO, placebo; PERT, pertuzumab; PFS, progression-free survival; TRAS, trastuzumab; TUC, tucatinib.

A

PFS

FIG A2. · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

PFS

FIG A2. · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 FIG A2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure2 个面板

FIG A3.

FIG A3. Kaplan-Meier estimates of (A) investigator-assessed CNS-PFS in the ITT analysis population and (B) patients with BM at baseline. BM, brain metastases; HR, hazard ratio; ITT, intention-to-treat; PBO, placebo; PERT, pertuzumab; PFS, progression-free survival; TRAS, trastuzumab; TUC, tucatinib.

A

CNS-PFS

FIG A3. · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

CNS-PFS

FIG A3. · Panel B

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel B 是同一 FIG A3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram of the HER2CLIMB-05 study. a Three patients were randomly assigned to the PBO + TRAS + PERT arm but received some doses of TUC; these three patients were included in the TUC + TRAS + PERT arm for the safety analysis. AE, adverse event; PBO, placebo; PERT, pertuzumab; TRAS, trastuzumab; TUC, tucatinib.
非 KM Figure